The 4 Wall Street analysts covering Atrium Therapeutics, Inc. hold a median 12-month price target of $25 — +202.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 5 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Atrium Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (77): Analysts have, on balance, been raising their forecasts.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RNA, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +202.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 6 Aug 2026 | HC Wainwright & Co. | Initiates | Buy | $25 |
| 6 Aug 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 18 June 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 18 June 2026 | Cantor Fitzgerald | Initiates | Overweight | $25 |
| 15 May 2026 | Leerink Partners | Initiates | Outperform | — |
| 11 Mar 2026 | Wells Fargo | Initiates | Overweight | — |
| 11 Nov 2025 | Chardan Capital | Maintains | Neutral | — |
| 29 Oct 2025 | TD Cowen | Downgrade | Hold | — |
| 28 Oct 2025 | Chardan Capital | Downgrade | Neutral | — |
| 28 Oct 2025 | RBC Capital | Downgrade | Sector Perform | — |
| 27 Oct 2025 | Bernstein | Downgrade | Market Perform | — |
| 27 Oct 2025 | Citigroup | Downgrade | Neutral | — |
| 27 Oct 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 27 Oct 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 27 Oct 2025 | Needham | Downgrade | Hold | — |
| 27 Oct 2025 | Raymond James | Downgrade | Market Perform | — |
| 22 Sept 2025 | Evercore ISI Group | Maintains | Outperform | — |
| 17 Sept 2025 | Roth Capital | Initiates | Buy | — |
| 15 Sept 2025 | B of A Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RNA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 31% of US stocks
Cheaper than 81% of US stocks
Cheaper than 57% of US stocks
Higher than 11% of US stocks
Higher than 96% of US stocks
Higher than 6% of US stocks
Higher than 3% of US stocks
Higher than 25% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Atrium Therapeutics, Inc. has a market value of $135.6M and an enterprise value of −$125.5M.
Revenue in the twelve months to 30 June 2026: $35.8M. The latest quarter shrank 21.9% year on year.
Net income over the same four quarters: −$93.2M, a −260.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$56.5M.
Trailing P/E: −2.8×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Atrium Therapeutics, Inc. employs 511 people — $70K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Atrium Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Atrium Therapeutics entered into a securities purchase agreement with institutional investors for a private placement expected to generate approximately $50 million in gross proceeds, before fees and other offering expenses.
Why it matters — The financing would provide Atrium with capital from the private placement, a development relevant to investors tracking the company.
Atrium Therapeutics announced it awarded inducement grants on September 20, 2026 under its 2026 Employment Inducement Incentive Award Plan as a material inducement to the employment of one newly hired non-executive individual.
Why it matters — The grant indicates Atrium is hiring new personnel, a routine corporate action that may signal modest team expansion but carries no direct business impact.
Atrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company developing RNA therapeutics for precision cardiology, announced it will participate in upcoming investor conferences in September.
Why it matters — RNA watchers would see this as an opportunity for the company to communicate its progress and pipeline to investors at industry events.
Atrium Therapeutics announced on August 20, 2026 that it awarded inducement grants to a newly hired non-executive employee under its 2026 Employment Inducement Incentive Award Plan, consisting of non-qualified stock options for 11,000 shares at $13.48 per share and restricted stock units for 5,500 shares, both subject to vesting schedules tied to continued service.
Why it matters — RNA watchers would care because the equity incentive grants signal the company's efforts to attract and retain new talent, potentially affecting its share count and compensation structure.
Atrium Therapeutics reported its second quarter 2026 financial results, highlighting FDA clearance of its Investigational New Drug application for ATR 1072 and the launch of its Phase 1/2 Corventis trial, the first clinical study evaluating a potential disease-modifying treatment for PRKAG2 syndrome. The company also noted it achieved a second milestone payment under its global cardiovascular collaboration with Bristol Myers Squibb.
Why it matters — RNA watchers would care because the company is advancing its lead RNA-therapeutic candidate into the clinic and strengthening its BMS partnership, marking key progress in its precision cardiology pipeline.
The 4 Wall Street analysts covering Atrium Therapeutics, Inc. have a median 12-month price target of $25, with estimates ranging from $25 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Atrium Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atrium Therapeutics, Inc. 5 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Atrium Therapeutics, Inc. ranks 5 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (77 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +202.7% from the last close, and Ticker Nerd's factor model ranks Atrium Therapeutics, Inc. 5 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Atrium Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $25 over the next 12 months.
Atrium Therapeutics, Inc. is a biopharmaceutical company focused on precision cardiology through targeted RNA therapeutics for heart disease.
The most recent item we track (PRNewsWire, 8 Oct 2026): "Atrium Therapeutics Announces $50 Million Private Placement". Atrium Therapeutics entered into a securities purchase agreement with institutional investors for a private placement expected to generate approximately $50 million in gross proceeds, before fees and other offering expenses.
Atrium Therapeutics, Inc. is a biopharmaceutical company focused on precision cardiology through targeted RNA therapeutics for heart disease. The company develops therapies designed to deliver ribonucleic acid medicines directly to cardiac tissue, using a proprietary delivery platform that combines tissue-selective targeting with oligonucleotide precision. Its current pipeline centers on rare genetic cardiomyopathies, including ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy. Atrium Therapeutics also advances research programs aimed at additional rare cardiac conditions, reflecting its focus on genetically defined diseases with significant unmet medical need. Based in San Diego, California, Atrium Therapeutics operates as a specialist developer in the broader biotechnology sector, with a business model centered on translating RNA science into potential treatments for inherited heart disorders.
CEO Ms. Kathleen P. Gallagher · 511 employees · United States · https://atriumtherapeutics.com